Sorafenib: Difference between revisions
From OncoWiki
Jump to navigationJump to search
m (1 revision) |
(No difference)
|
Latest revision as of 02:18, 7 February 2012
Drug information
- Nexavar is a targeted therapy. Nexavar is classified as a, tyrosine kinase inhibitor, angiogenesis inhibitor, VEGF inhibitor.
- Prescribing information (Bayer, PDF)
- Nexavar Use and Side Effects Information
Regimen
Hepatocellular carcinoma
- Sorafenib (Nexavar) 400 mg po bid
References
Kidney Renal Cell Cancer
- Sorafenib (Nexavar) 400 mg po bid
Approved by FDA on 12/20/2005
References
Escudier B et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356:125